Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension.
RMD Open. 2021 Sep;7(3):e001714. doi: 10.1136/rmdopen-2021-001714.
RMD Open. 2021.
PMID: 34548383
Free PMC article.
Clinical Trial.